Cancer Home > Ipilimumab

Available by prescription only, ipilimumab is used to treat a serious form of skin cancer called melanoma. It comes as an injection that is administered intravenously by your healthcare provider every three weeks for up to four doses. Although this can be an effective medicine, it may not be suitable for some people who are taking certain medications or who have certain medical conditions.

What Is Ipilimumab?

Ipilimumab (Yervoy™) is a prescription medication approved to treat melanoma, a dangerous type of skin cancer, when it has spread to other areas of the body (metastasized) or cannot be removed with surgery. It belongs to a group of medicines called monoclonal antibodies.
 
(Click What Is Ipilimumab Used For? for more information on this topic, including possible off-label uses.)
 

Are There Side Effects?

Just like any medicine, ipilimumab can cause side effects. However, not everyone who receives the drug will experience problems. Most people tolerate it quite well.
 
If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious reactions are less common.
 
Some of the common side effects seen with ipilimumab include:
 
 
(Click Ipilimumab Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation
Advertisement


Topics

Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2017 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.